CIDP
MCID: CHR283
MIFTS: 47

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Categories: Immune diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyneuropathy:

Name: Chronic Inflammatory Demyelinating Polyneuropathy 53 54 59 38 17
Chronic Inflammatory Demyelinating Polyradiculoneuropathy 53 59
Cidp 53 59
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 72

Characteristics:

Orphanet epidemiological data:

59
chronic inflammatory demyelinating polyneuropathy
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 34 G61.8
UMLS via Orphanet 73 C0393819
Orphanet 59 ORPHA2932
UMLS 72 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyneuropathy

NIH Rare Diseases : 53 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. Symptoms often include tingling or numbness (first in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes, fatigue, and abnormal sensations. Other symptoms may include pain, difficulty swallowing (dysphagia), and double vision (diplopia). CIDP is thought to be caused by the immune system mistakenly attacking and damaging the myelin sheath (protective cover of nerve fibers) of the peripheral nerves. CIDP is closely related to Guillain-Barre syndrome (GBS) and is considered the "chronic counterpart" of GBS. Treatment may include corticosteroids, immunosuppressant drugs, plasma exchange, physical therapy, and/or intravenous immunoglobulin (IVIG) therapy. Left untreated, 30% of people with CIDP will progress to wheelchair dependence.

MalaCards based summary : Chronic Inflammatory Demyelinating Polyneuropathy, also known as chronic inflammatory demyelinating polyradiculoneuropathy, is related to peripheral nervous system disease and demyelinating polyneuropathy. An important gene associated with Chronic Inflammatory Demyelinating Polyneuropathy is AIF1 (Allograft Inflammatory Factor 1), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and L1CAM interactions. The drugs Amifampridine and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and spinal cord, and related phenotypes are fatiguable weakness of proximal limb muscles and areflexia

NINDS : 54 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder, which is sometimes called chronic relapsing polyneuropathy, is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women. It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

Wikipedia : 75 Chronic inflammatory demyelinating polyneuropathy is an acquired immune-mediated inflammatory disorder... more...

Related Diseases for Chronic Inflammatory Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Chronic Inflammatory Demyelinating Polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy
Acute and Subacute Inflammatory Demyelinating Polyneuropathy Chronic Acquired Demyelinating Polyneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 317)
# Related Disease Score Top Affiliating Genes
1 peripheral nervous system disease 29.6 TTR NFASC
2 demyelinating polyneuropathy 29.6 TTR NFASC HP CNTN2 AIF1
3 lewis-sumner syndrome 11.8
4 x-linked charcot-marie-tooth disease 11.5
5 polyneuropathy 11.5
6 guillain-barre syndrome, familial 11.2
7 guillain-barre syndrome 10.9
8 neuropathy 10.9
9 polyradiculoneuropathy 10.8
10 chronic inflammatory demyelinating polyradiculoneuropathy 10.7
11 autoimmune disease 10.7
12 ataxia and polyneuropathy, adult-onset 10.6
13 sensory peripheral neuropathy 10.6
14 axonal neuropathy 10.6
15 multifocal motor neuropathy 10.6
16 charcot-marie-tooth disease 10.6
17 respiratory failure 10.5
18 myasthenia gravis 10.5
19 tooth disease 10.5
20 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.5
21 diabetic polyneuropathy 10.5
22 quadriplegia 10.5
23 demyelinating disease 10.5
24 tremor 10.5
25 amyotrophic lateral sclerosis 1 10.4
26 locked-in syndrome 10.4
27 poems syndrome 10.4
28 neuritis 10.4
29 lateral sclerosis 10.4
30 monoclonal gammopathy of uncertain significance 10.4
31 lupus erythematosus 10.4
32 diabetes mellitus 10.4
33 exophthalmos 10.4
34 systemic lupus erythematosus 10.4
35 autoimmune neuropathy 10.4
36 mononeuropathy 10.4
37 miller fisher syndrome 10.4
38 mononeuritis multiplex 10.4
39 melanoma 10.4
40 hereditary neuropathies 10.4
41 relapsing-remitting multiple sclerosis 10.3
42 muscular atrophy 10.3
43 dysphagia 10.3
44 membranous nephropathy 10.3
45 ptosis 10.3
46 myopathy 10.3
47 neuromuscular disease 10.3
48 crohn's disease 10.3
49 diabetic neuropathy 10.3
50 acute motor axonal neuropathy 10.3

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyneuropathy

Human phenotypes related to Chronic Inflammatory Demyelinating Polyneuropathy:

59 32 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatiguable weakness of proximal limb muscles 59 32 hallmark (90%) Very frequent (99-80%) HP:0030200
2 areflexia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001284
3 paresthesia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003401
4 unsteady gait 59 32 hallmark (90%) Very frequent (99-80%) HP:0002317
5 segmental peripheral demyelination/remyelination 59 32 hallmark (90%) Very frequent (99-80%) HP:0003481
6 sensory ataxia 59 32 hallmark (90%) Very frequent (99-80%) HP:0010871
7 motor conduction block 59 32 hallmark (90%) Very frequent (99-80%) HP:0012078
8 falls 59 32 frequent (33%) Frequent (79-30%) HP:0002527
9 difficulty walking 59 32 frequent (33%) Frequent (79-30%) HP:0002355
10 difficulty climbing stairs 59 32 frequent (33%) Frequent (79-30%) HP:0003551
11 hand muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0030237
12 spontaneous pain sensation 59 32 occasional (7.5%) Occasional (29-5%) HP:0010833
13 peripheral neuropathy 59 Very frequent (99-80%)
14 decreased nerve conduction velocity 59 Very frequent (99-80%)
15 peripheral demyelination 59 Very frequent (99-80%)
16 sensory impairment 59 Very frequent (99-80%)
17 abnormal nerve conduction velocity 59 Very frequent (99-80%)

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amifampridine Approved, Investigational Phase 3 54-96-6
2
Mycophenolic acid Approved Phase 3 24280-93-1 446541
3
tannic acid Approved Phase 3 1401-55-4
4
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
5
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
6 Immunoglobulin G Phase 3
7 Antibodies Phase 3
8 Immunoglobulins Phase 3
9 Immunoglobulins, Intravenous Phase 3
10 gamma-Globulins Phase 3
11 Rho(D) Immune Globulin Phase 3
12 Fingolimod Hydrochloride Phase 3
13 Neuromuscular Agents Phase 3
14 Potassium Channel Blockers Phase 3
15 Anti-Bacterial Agents Phase 3
16 Antitubercular Agents Phase 3
17 Antibiotics, Antitubercular Phase 3
18 Pharmaceutical Solutions Phase 2, Phase 3
19
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
20
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
21
Carmustine Approved, Investigational Phase 2 154-93-8 2578
22
Etoposide Approved Phase 2 33419-42-0 36462
23
Melphalan Approved Phase 2 148-82-3 460612 4053
24
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
25
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
26
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
27
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
28
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
29
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
30
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
31
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
32
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
33
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
35
Cortisone Experimental Phase 2 53-06-5 222786
36
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
37 Interferon-beta Phase 2
38 interferons Phase 2
39 Trace Elements Phase 2
40 Micronutrients Phase 2
41 Alpha-lipoic Acid Phase 2
42 Antioxidants Phase 2
43 Vitamins Phase 2
44 Vitamin B9 Phase 2
45 Nutrients Phase 2
46 Vitamin B Complex Phase 2
47 Folate Phase 2
48 Thioctic Acid Phase 2
49 Autoantibodies Phase 2
50 Antiviral Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting NCT03684018 Phase 4
3 An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
5 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
6 A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
7 An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02293460 Phase 3 I10E
8 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
9 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
10 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
12 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
13 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
14 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
15 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
16 Does the Mycophenolate Improve the Ability of Weaning Patients Off the Treatment in Chronic Inflammatory Demyelinating Polyradiculopathy (CIDP) Completed NCT02494505 Phase 3 Mycophenolate Mofetil;placebo
17 Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02955355 Phase 3
18 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02549170 Phase 3
19 Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy Active, not recruiting NCT02638207 Phase 3 NewGam
20 International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302" Terminated NCT02317562 Phase 3 I10E
21 Double-blind, Placebo-controlled, Randomised, Multicentre, Adaptive, Two-stage Phase 2/3 Study Evaluating Safety and Efficacy of Three Dosages of NewGam in CIDP Patients Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
22 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
23 Randomised, Double-blinded, Placebo-controlled Trial of Subcutaneous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
24 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
25 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy—A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
26 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
27 Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes Completed NCT02343211 Phase 2 Immunoglobulin
28 Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: a Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety. Completed NCT02637700 Phase 2 Intravenous Immunoglobulin;Placebo
29 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Recruiting NCT03864185 Phase 2
30 A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT03861481 Phase 2 Rozanolixizumab
31 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases Recruiting NCT00716066 Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan;Prednisone
32 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Active, not recruiting NCT00278629 Phase 2
33 Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia Active, not recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
34 IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS) Enrolling by invitation NCT03919773 Phase 1, Phase 2 IVIG;Albumin
35 An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Not yet recruiting NCT04051944 Phase 2 Rozanolixizumab
36 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
37 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
38 A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-06755347 AFTER SINGLE ASCENDING INTRAVENOUS INFUSIONS TO HEALTHY ADULT MALE PARTICIPANTS Recruiting NCT03275740 Phase 1 PF-06755347;Placebo comparator
39 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
40 Magnetic Resonance Imaging and Ultrasound Imaging of Peripheral Nerves in Patients Treated With Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02017769
41 "Clinical Study of Intravenous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy" Completed NCT00305266 intravenous gammaglobulin
42 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01379833
43 MRI of the Brachial Plexus and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Assessment of DTI-derived Measurements at 3.0-T Completed NCT03460951
44 Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) Completed NCT02121678
45 The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN Completed NCT02111590 Immunoglobulins
46 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
47 A Patient Centered Intervention to Improve Health and Reduce Medicaid Costs Completed NCT01602848
48 A Multicenter Pilot Study to Determine Criteria for Evaluating the Effectiveness of Two Comparative Monitoring Methods in the Management of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Receiving Home-based Treatment With IVIg (Privigen®) Recruiting NCT03779828
49 Biomarker to Predict the Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients: a Transcriptomic Study Recruiting NCT02629796
50 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG Recruiting NCT03008733

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyneuropathy

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Immune Globulin Human
Immunoglobulins, Intravenous

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Chronic Inflammatory Demyelinating Polyneuropathy:
Hematopoietic stem cells for treatment of chronic inflammatory demyelinating polyneuropathy
Embryonic/Adult Cultured Cells Related to Chronic Inflammatory Demyelinating Polyneuropathy:
Bone marrow-derived hematopoietic stem cells PMIDs: 17277794

Genetic Tests for Chronic Inflammatory Demyelinating Polyneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyneuropathy:

41
T Cells, Skin, Spinal Cord, Testes, Bone, Brain, Endothelial

Publications for Chronic Inflammatory Demyelinating Polyneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyneuropathy:

(show top 50) (show all 2205)
# Title Authors PMID Year
1
Comparison of high-frequency and ultrahigh-frequency probes in chronic inflammatory demyelinating polyneuropathy. 38
31175432 2019
2
Spinal cord stimulation in the treatment of neuropathic pain in chronic inflammatory demyelinating polyneuropathy. 38
31221583 2019
3
Neuropathy associated with immunoglobulin M monoclonal gammopathy: A combined sonographic and nerve conduction study. 38
31269243 2019
4
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. 38
31355323 2019
5
Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. 38
31227562 2019
6
Serial nerve ultrasound and motor nerve conduction studies in chronic inflammatory demyelinating polyradiculoneuropathy. 38
31206194 2019
7
Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. 38
30992333 2019
8
Clinical factors, diagnostic delay and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. 38
31410938 2019
9
Validation of the Serbian version of I-RODS in patients with chronic inflammatory demyelinating polyradiculoneuropathy. 38
31397933 2019
10
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. 38
31076244 2019
11
Conduction block in immune-mediated neuropathy: paranodopathy versus axonopathy. 38
30882969 2019
12
Subcutaneous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Nursing Perspective. 38
31107344 2019
13
Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis. 38
30989684 2019
14
Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH Study. 38
31400231 2019
15
Immune Globulin Subcutaneous (Human) 20% (Hizentra®): A Review in Chronic Inflammatory Demyelinating Polyneuropathy. 38
31347096 2019
16
Clinical-neurophysiological correlations in CIDP patients treated with subcutaneous immunoglobulin. 38
31415091 2019
17
Corrigendum to "MR microneurography and quantitative T2 and DP measurements of the distal tibial nerve in CIDP" [Journal of the Neurological Sciences Volume 400, 15 May 2019, Pages 15-20]. 38
31178081 2019
18
Tonic pupils: an unusual autonomic involvement in chronic inflammatory demyelinating polyneuropathy (CIDP). 38
30997592 2019
19
Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. 38
31072742 2019
20
Causes of chronic neuropathies: a single-center experience. 38
31001716 2019
21
Neurological manifestations related to Crohn's disease: a boon for the workforce. 38
31413837 2019
22
Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation. 38
31048087 2019
23
Intravenous immunoglobulin G use in patients with chronic inflammatory demyelinating polyneuropathy: An uncommon cause of drug-induced discoid lupus erythematosus. 38
30734274 2019
24
Long-term successful treatment of chronic inflammatory demyelinating polyneuropathy-like polyneuropathy induced by levodopa-carbidopa intestinal gel with intravenous immunoglobulin. 38
31330074 2019
25
Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: A potential role in monitoring response to intravenous immunoglobulins. 38
31400577 2019
26
Clinical and electrophysiological profiles in early recognition of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome. 38
31268911 2019
27
Prospective study of the additional benefit of plexus magnetic resonance imaging in the diagnosis of chronic inflammatory demyelinating polyneuropathy. 38
31348848 2019
28
Completing the Immunological Fingerprint by Refractory Proteins: Autoantibody Screening via an Improved Immunoblotting Technique. 38
30768763 2019
29
Nerve ultrasound can identify treatment-responsive chronic neuropathies without electrodiagnostic features of demyelination. 38
31294858 2019
30
Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. 38
31325350 2019
31
Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy. 38
31306213 2019
32
Differentiation Between Guillain-Barré Syndrome and Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuritis-a Prospective Follow-up Study Using Ultrasound and Neurophysiological Measurements. 38
30756363 2019
33
Orbital Neuromas Associated With Chronic Inflammatory Demyelinating Polyneuropathy. 38
31365508 2019
34
[Chronic inflammatory demyelinating polyneuropathy]. 38
31364968 2019
35
Pain in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. 38
31201680 2019
36
One-year follow-up study of neuropathic pain in chronic inflammatory demyelinating polyradiculoneuropathy. 38
30973184 2019
37
Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy. 38
31090121 2019
38
Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. 38
31176377 2019
39
Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy. 38
31209940 2019
40
Electrodiagnostic data-driven clustering identifies a prognostically different subgroup of patients with chronic inflammatory demyelinating polyneuropathy. 38
30904899 2019
41
Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. 38
30973667 2019
42
[Clinical analysis of 8 cases with anti-GQ1b antibody syndrome]. 38
31207691 2019
43
Chronic immune sensorimotor polyradiculopathy: Report of a case series. 38
30697760 2019
44
Immediate hypersensitivity reaction to human serum albumin in a child undergoing plasmapheresis. 38
30758852 2019
45
Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. 38
30903535 2019
46
Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin. 38
31318515 2019
47
Neurofascin (NFASC) gene mutation causes autosomal recessive ataxia with demyelinating neuropathy. 38
30850329 2019
48
Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis. 38
31346365 2019
49
Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome. 38
30756171 2019
50
Tongue tremor in neurofascin-155 IgG4 seropositive chronic inflammatory polyradiculoneuropathy. 38
30713112 2019

Variations for Chronic Inflammatory Demyelinating Polyneuropathy

Expression for Chronic Inflammatory Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyneuropathy

Pathways related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.12 NFASC CNTN2
2
Show member pathways
10.72 NFASC CNTN2

GO Terms for Chronic Inflammatory Demyelinating Polyneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.65 CNTN2
2 node of Ranvier GO:0033268 8.62 NFASC CNTN2

Biological processes related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.13 TTR NFASC HP
2 protein localization to juxtaparanode region of axon GO:0071205 8.62 NFASC CNTN2

Sources for Chronic Inflammatory Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....